Pfizer Receives Average Rating of “Buy” from Brokerages (NYSE:PFE)
Shares of Pfizer (NYSE:PFE) have been given an average recommendation of “Buy” by the eighteen ratings firms that are currently covering the stock, Analyst Ratings News reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $32.83.
In other Pfizer news, Insider Geno J. Germano sold 30,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $29.68, for a total value of $890,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on PFE shares. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Pfizer in a research note on Wednesday, May 28th. They set an “overweight” rating and a $35.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, May 27th. They now have a $31.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pfizer in a research note on Tuesday, May 27th. They set a “buy” rating on the stock.
Shares of Pfizer (NYSE:PFE) traded up 0.10% on Tuesday, hitting $29.3792. The stock had a trading volume of 4,360,268 shares. Pfizer has a 52-week low of $27.33 and a 52-week high of $32.96. The stock’s 50-day moving average is $29.90 and its 200-day moving average is $30.91. The company has a market cap of $187.4 billion and a price-to-earnings ratio of 9.11.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.01. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the previous year, the company posted $0.54 earnings per share. The company’s revenue for the quarter was down 8.5% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.24 earnings per share for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.